Summary and Considerations in the Nursing Care of Patients with Progressive Familial Intrahepatic Cholestasis
American Journal of Nursing Science
Volume 9, Issue 5, October 2020, Pages: 310-315
Received: Aug. 3, 2020;
Accepted: Aug. 13, 2020;
Published: Aug. 19, 2020
Views 179 Downloads 47
Ni Zhang, College of Nursing, Jinan University, Guangzhou, China
Yuanzong Song, Department of Neonatal, The First Affiliated Hospital of Jinan University, Guangzhou, China
Meixue Chen, College of Nursing, Jinan University, Guangzhou, China
Lingli Cai, College of Nursing, Jinan University, Guangzhou, China
Manli Liu, College of Nursing, Jinan University, Guangzhou, China
Weiwei Wang, College of Nursing, Jinan University, Guangzhou, China
Qingran Lin, Department of Nursing, The First Affiliated Hospital of Jinan University, Guangzhou, China
Background: Progressive familiar intrahepatic cholestasis (PFIC) is a group of rare cholestatic liver diseases whose main features are itching, jaundice and even liver failure. Many studies have been reported in clinical reports, but the care of PFIC is rarely described. Purpose: To provide a summary and recommendations for the setup of strategies for PFIC patient care. Material and methods: A non-systematic review of PFIC nursing research until July 12, 2020. Use online search engines (PubMed, Medline, Embase, Web of Science, and CINAHL) to find PFIC nursing-related content, sort and summarize nursing-related content. Results: As a rare disease, there is limited research in PFIC nursing. The main care measures of PFIC including nursing interventions and evaluation tools. Nursing intervention is divided into general symptom care and nursing care of postoperative complications. Evaluation tools mainly focus on quality of life assessment and evaluation of itching. Conclusions: Nurses should pay attention to the use of scales when caring for PFIC patients, and observe whether specific nursing measures can help improve patients’ quality of life. PFIC nursing interventions and evaluation tools should be tailored according to PFIC clinical manifestation. A multidisciplinary collaborative approach is encouraged for proper management and tailoring therapy according to clinical manifestation.
Summary and Considerations in the Nursing Care of Patients with Progressive Familial Intrahepatic Cholestasis, American Journal of Nursing Science.
Vol. 9, No. 5,
2020, pp. 310-315.
Bull LN, Thompson RJ. Progressive Familial Intrahepatic Cholestasis. Clin Liver Dis. 2018; 22 (4): 657-669.
Gaur K, Sakhuja P. Progressive familial intrahepatic cholestasis: A comprehensive review of a challenging liver disease. Indian J Pathol Microbiol. 2017; 60 (1): 2-7.
Gunaydin M, Bozkurter Cil AT. Progressive familial intrahepatic cholestasis: diagnosis, management, and treatment. Hepat Med. 2018; 10: 95-104.
Alastair B, Nanda K, Lora T, et al. Systematic review of progressive familial intrahepatic cholestasis. [J]. Clinics and research in hepatology and gastroenterology, 2019, 43 (1).
The 22nd Conference of the Asian Pacific Association for the Study of the Liver: APASL 2012-Taipei, Taiwan-16-19 February. [Z]. 2012: 6.
Torfgard K, Gwaltney C, Paty J, et al. Symptoms and daily impacts associated with progressive familial intrahepatic cholestasis and other pediatric cholestatic liver diseases: A qualitative study with patients and caregivers [J]. Journal of Pediatric Gastroenterology and Nutrition, 2018, 67: S208-S209.
Serrano D, Gauthier M, Harrington M, et al. Psychometric validation of the Itch-Reported Outcome (ItchRO™) assessment in pediatric patients with Alagille syndrome or progressive familial intrahepatic cholestasis [J]. Hepatology, 2016, 64 (1): 284A-285A.
Van Vaisberg V, Tannuri ACA, Lima FR, Tannuri U. Ileal Exclusion for Pruritus Treatment in Children with Progressive Familial Intrahepatic Cholestasis and other Cholestatic Diseases [published online ahead of print, 2019 Nov 5]. J Pediatr Surg. 2019; S0022-3468 (19) 30664-5.
Arnell H, Bergdahl S, Papadogiannakis N, Nemeth A, Fischler B. Preoperative observations and short-term outcome after partial external biliary diversion in 13 patients with progressive familial intrahepatic cholestasis. J Pediatr Surg. 2008; 43 (7): 1312-1320.
E J, D H, A M, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. [J]. Hepatology, 1997, 25 (3).
Abdelhamid N, Elkoofy N, Ghobrial C, et al. Zinc status in infants and children with cholestatic liver diseases and its effect on growth [J]. Journal of Pediatric Gastroenterology and Nutrition, 2018, 66: 1116.
Racha K, Claudia P, Sara K, et al. Cholestasis beyond the Neonatal and Infancy Periods. [J]. Pediatric gastroenterology, hepatology & nutrition, 2016 (1): 1-11.
Kaur S, Sharma D, Wadhwa N, et al. Therapeutic interventions in progressive familial intrahepatic cholestasis: Experience from a tertiary care centre in North India [J]. Indian Journal of Pediatrics, 2012, 79 (2): 270-273.
Nemati H, Kazemi K, Mokarram A T. Neurological Complications associated with Pediatric Liver Transplant in Namazi Hospital: One-Year Follow-Up [J]. Int J Organ Transplant Med, 2019, 10 (1): 30-35.
The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties [J]. Soc Sci Med, 1998, 46 (12): 1569-1585.
Yee K, Moshkovich O, Llewellyn S, et al. A web-based survey of itch severity after surgical treatment of progressive familial intrahepatic cholestasis in children and adolescents [J]. Hepatology, 2018, 68: 1047A.
PedsQL 4.0 [M]//GELLMANM D, TURNER J R. Encyclopedia of Behavioral Medicine. New York, NY: Springer New York, 2013: 1449.
Wassman S, Pfister E D, Kuebler J F, et al. Quality of life in patients with progressive familial intrahepatic cholestasis: No difference between post-liver transplantation and post-partial external biliary diversion [J]. Journal of Pediatric Gastroenterology and Nutrition, 2018, 67 (5): 643-648.
Varni J W, Seid M, Rode C A. The PedsQL: measurement model for the pediatric quality of life inventory [J]. Med Care, 1999, 37 (2): 126-139.
Kamath B M, Abetz-Webb L, Kennedy C, et al. Development of a Novel Tool to Assess the Impact of Itching in Pediatric Cholestasis [J]. Patient, 2018, 11 (1): 69-82.
Kennedy C, Abetz-Webb L, Lambe J. Challenges in recruiting patients for the linguistic validation of pro instruments developed for rare diseases: A case study with alagille syndrome [J]. Value in Health, 2014, 17 (7): A575.
S E, S H L, V G, et al. The 5-D itch scale: a new measure of pruritus. [J]. The British journal of dermatology, 2010, 162 (3).
Hsiao C H, Chang M H, Chen H L, et al. Universal screening for biliary atresia using an infant stool color card in Taiwan [J]. Hepatology, 2008, 47 (4): 1233-1240.
Chan P, Soon Y, Bennett T, et al. The performance and effciency of the infant stool color card as a screening tool for biliary atresia: A systematic review [J]. Journal of Gastroenterology and Hepatology, 2019, 34: 205.
Kwak A, Dabrowska M, Jankowska I, et al. Health related quality of life in children with progressive familial intrahepatic cholestasis after partial external biliray diversion [J]. Pediatria Wspolczesna, 2005, 7 (3): 201-204.
Vimalesvaran S, Nevus L, Deheragoda M, et al. Allograft histology and biopsychosocial health 10 years after liver transplantation in children [J]. Transplantation, 2019, 103 (8): 92.